Journal
CELL DEATH & DISEASE
Volume 12, Issue 7, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-021-03947-7
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81772706]
Ask authors/readers for more resources
ALPK2 plays a cancer-promoting role in bladder cancer by regulating DEPDC1A, which may serve as a promising target for improving the treatment strategy of bladder cancer. The interaction between ALPK2 and DEPDC1A could control the malignant behavior of bladder cancer cells, making them potential therapeutic targets.
Bladder cancer is one of the most common malignant tumors in the urinary system. The development and improvement of treatment efficiency require the deepening of the understanding of its molecular mechanism. This study investigated the role of ALPK2, which is rarely studied in malignant tumors, in the development of bladder cancer. Our results showed the upregulation of ALPK2 in bladder cancer, and data mining of TCGA database showed the association between ALPK2 and pathological parameters of patients with bladder cancer. In vitro and in vivo experiments demonstrated that knockdown of ALPK2 could inhibit bladder cancer development through regulating cell proliferation, cell apoptosis, and cell migration. Additionally, DEPDC1A is identified as a potential downstream of ALPK2 with direct interaction, whose overexpression/downregulation can inhibit/promote the malignant behavioral of bladder cancer cells. Moreover, the overexpression of DEPDC1A can rescue the inhibitory effects of ALPK2 knockdown on bladder cancer. In conclusion, ALPK2 exerts a cancer-promoting role in the development of bladder cancer by regulating DEPDC1A, which may become a promising target to improve the treatment strategy of bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available